Keller Rohrback L.L.P. Announces Investigation of Psoriasis Drug Raptiva


SEATTLE, April 8, 2009 (GLOBE NEWSWIRE) -- Attorney Advertising. Keller Rohrback L.L.P. (www.krclassaction.com) announces that it has commenced an investigation of Raptiva, a drug manufactured by Genentech Inc., a unit of Roche Holdings AG (ROG.VX). Raptiva is used in the treatment of psoriasis. Genentech recently announced that it was voluntarily withdrawing Raptiva from the U.S. market after it was linked to an increased risk of Progressive Multifocal Leukoencephalopathy ("PML"), an often fatal brain disorder.

If you or someone you know has been injured as a result of taking Raptiva, or you would like additional information regarding this investigation, please contact attorneys Mike Woerner or Lynn Sarko at (800) 776-6044 (Seattle) or Mark Samson at (602) 248-0088 (Phoenix), or via email at info@kellerrohrback.com.

Keller Rohrback L.L.P. has successfully represented hundreds of clients injured by prescription drugs such as Fen-Phen, Baycol, and Vioxx. Our Complex Litigation Group is proud to offer its expertise in personal injury cases to clients nationwide. Keller Rohrback's trial lawyers have obtained judgments and settlements on behalf of clients in excess of seven billion dollars.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.



            

Tags


Contact Data